Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
CRANBURY, N.J. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, Arizona on Wednesday, November
View HTML
Toggle Summary Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
U.S. Galafold ® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch 3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued International Growth - 500+ International Fabry Patients Now on Galafold Reaffirming
View HTML
Toggle Summary Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018
CRANBURY, N.J. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2018 .
View HTML
Toggle Summary Amicus Therapeutics to Host Analyst Day 2018 Today in New York City
Management and External Thought Leaders to Highlight Robust Portfolio of Novel Therapies for Rare Metabolic Diseases Webcast Scheduled from 8:30am – 12:30pm E.T. CRANBURY, N.J. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDAQ: FOLD), a global biotechnology company focused on
View HTML
Toggle Summary Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
Collaboration Focuses on Four Genetic Disorders: Pompe, Fabry, CDKL5 and One Additional Undisclosed Rare Metabolic Disorder Combines Amicus Expertise in Protein Engineering with Penn’s AAV Vector Technology, Manufacturing and Immunology Capabilities Leverages The Wilson Lab’s Extensive
View HTML
Toggle Summary Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society
Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue Out to Month 18 for both ERT-Naïve and ERT-Switch Patients Very Low Rate (
View HTML
Toggle Summary Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society
CRANBURY, N.J. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the 23rd International Congress of the World Muscle Society , to be held
View HTML
Toggle Summary Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
CRANBURY, N.J. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY
View HTML
Toggle Summary Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
License with Nationwide Children’s Hospital ( NCH ) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases              
View HTML
Toggle Summary Amicus Therapeutics Announces Board Appointments
Lynn D. Bleil Appointed to Board of Directors Michael G. Raab Named Lead Independent Director CRANBURY, N.J. , Sept. 11, 2018 (GLOBE NEWSWIRE) --  Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic
View HTML